Uniqure’s (QURE) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Uniqure (NASDAQ:QURE) in a research note published on Monday, Marketbeat.com reports. They currently have a $73.00 price target on the biotechnology company’s stock, up from their prior price target of $60.00.

Other analysts also recently issued research reports about the stock. Zacks Investment Research downgraded shares of Uniqure from a buy rating to a hold rating in a report on Wednesday, October 17th. Chardan Capital reaffirmed a buy rating and issued a $50.00 price target on shares of Uniqure in a report on Thursday, October 18th. BidaskClub raised shares of Uniqure from a sell rating to a hold rating in a research note on Friday, October 19th. Leerink Swann upped their price objective on shares of Uniqure from $61.00 to $76.00 and gave the company a positive rating in a research note on Thursday, November 15th. Finally, Cantor Fitzgerald reissued a buy rating and set a $65.00 price objective on shares of Uniqure in a research note on Thursday, November 15th. Two research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $55.20.

Get Uniqure alerts:

NASDAQ QURE opened at $36.98 on Monday. The company has a current ratio of 7.56, a quick ratio of 7.56 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $1.39 billion, a price-to-earnings ratio of -12.58 and a beta of 0.87. Uniqure has a one year low of $20.29 and a one year high of $43.23.

In related news, SVP Alexander Edward Kuta III sold 1,052 shares of the company’s stock in a transaction that occurred on Monday, January 28th. The shares were sold at an average price of $31.29, for a total transaction of $32,917.08. Following the transaction, the senior vice president now owns 26,578 shares of the company’s stock, valued at $831,625.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Christian Klemt sold 1,479 shares of the company’s stock in a transaction that occurred on Monday, January 28th. The shares were sold at an average price of $31.29, for a total transaction of $46,277.91. Following the transaction, the chief accounting officer now directly owns 56,085 shares in the company, valued at approximately $1,754,899.65. The disclosure for this sale can be found here. Insiders have sold 43,014 shares of company stock worth $1,320,169 in the last three months. Insiders own 1.56% of the company’s stock.

A number of hedge funds have recently modified their holdings of QURE. FMR LLC increased its position in Uniqure by 16.6% during the second quarter. FMR LLC now owns 3,694,681 shares of the biotechnology company’s stock worth $139,659,000 after purchasing an additional 526,283 shares during the last quarter. Federated Investors Inc. PA increased its position in Uniqure by 43.5% during the third quarter. Federated Investors Inc. PA now owns 1,565,600 shares of the biotechnology company’s stock worth $56,972,000 after purchasing an additional 474,320 shares during the last quarter. Alps Advisors Inc. acquired a new position in Uniqure during the fourth quarter worth approximately $2,460,000. Henry James International Management Inc. acquired a new position in Uniqure during the third quarter worth approximately $2,852,000. Finally, Franklin Resources Inc. increased its position in Uniqure by 27.8% during the third quarter. Franklin Resources Inc. now owns 311,300 shares of the biotechnology company’s stock worth $11,328,000 after purchasing an additional 67,800 shares during the last quarter. 60.49% of the stock is owned by hedge funds and other institutional investors.

Uniqure Company Profile

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.

See Also: Trading Ex-Dividend

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.